APRIL 2010
Sessions will feature expert insight and analysis connecting federal policies to cancer research
Please join us in Washington, D.C., at the AACR 101st Annual Meeting 2010 to hear expert insight and analysis about the implications of federal policies on cancer research.
The AACR has organized three special policy sessions that will bring together distinguished scientific leaders to discuss the impact of recent and pending public policies on the future of cancer research.
Cancer Policy and Funding: How do we avoid falling off the funding cliff?
When: Monday, April 19, 5:00 p.m. - 6:00 p.m.
Where: Room 206, Walter E. Washington Convention Center, Washington, D.C.
Moderator: William Dalton, Moffitt Cancer Center
Panelists: Geoffrey Wahl, The Salk Institute; Cheryl Willman, University of New Mexico Cancer Center; Jon Retzlaff, American Association for Cancer Research
This panel discussion will focus on the current funding environment and ways in which the cancer research community can influence the legislative process. The panel will provide an overview of the funding landscape and the political process, including an update on the $10 billion investment of the American Recovery and Reinvestment Act, and the status of FY2011 appropriations. The panel will then discuss how best to advocate for the president’s initiative to double cancer research funding and will present current AACR initiatives.
Health Care Reform: The Confluence of Comparative Effectiveness, Health IT and Personalized Medicine
When: Tuesday, April 20, 10:30 a.m. – 12:00 p.m.
Where: Room 206, Walter E. Washington Convention Center, Washington, D.C.
Moderator: William Dalton, Moffitt Cancer Center
Panelists: Kenneth Buetow, National Cancer Institute; Amy Abernethy, Duke University; Edward Abrahams, Personalized Medicine Coalition; Ellen Sigal, Friends of Cancer Research
This panel discussion will focus on the effects of recent health care legislation on cancer researchers and the clinical research enterprise covering issues of comparative effectiveness research (CER), health information technology and personalized medicine. The impact of the expansion of CER by the American Recovery and Reinvestment Act and the health reform efforts, the current status of health information technology and the $11 billion in funding from the American Recovery and Reinvestment Act will be addressed. Panelists will discuss ways in which the CER and Health IT infrastructure can be configured to reap the benefits for the individual patient.
Integrating Science and Policy to Combat the Global Tobacco Epidemic
When: Tuesday, April 20, 4:00 p.m. - 5:30 p.m.
Where: Room 201, Walter E. Washington Convention Center, Washington, D.C.
Moderators: Ellen R. Gritz, M. D. Anderson Cancer Center, and Roy S. Herbst, M. D. Anderson Cancer Center
Participants: Thomas J. Glynn, American Cancer Society; K. "Vish" Viswanath, Harvard School of Public Health/Dana-Farber Cancer Institute; Robert T. Croyle, Cancer Control and Populations Sciences, NCI; Caryn Lerman, University of Pennsylvania Abramson Cancer Center; Matthew Myers, Campaign for Tobacco-Free Kids
Tobacco causes cancer at 18 different organ sites and is responsible for 30 percent of all cancer deaths in the U.S. The global burden of tobacco is on the rise and, if unchecked, tobacco will kill eight million people each year by 2030. To combat the tobacco problem, significant progress must be made both in tobacco control efforts and in the prevention and treatment of tobacco-related disease. A renewed and concerted effort across the spectrum of tobacco research is required to build the science base to develop effective policies and guide public health and clinical practice. In particular, new science is needed to fully realize the opportunity created by the passage of the Family Smoking Prevention and Tobacco Control Act in June 2009 granting the U.S. Food and Drug Administration authority over tobacco products. From impacts of marketing on children to the efficacy of nicotine-replacement therapies to improving the early detection of tobacco-related cancers, the cancer research community must collaborate to generate the much-needed evidence base to support the FDA in this historic undertaking. This special policy session will discuss the work of the AACR Task Force on Tobacco and Cancer in enumerating and prioritizing AACR activities addressing the tobacco problem, including the release of the AACR’s statement on tobacco - a call to action for the research community. A prestigious group of panelists will comment on the statement and a panel discussion with audience participation will follow.
Links:
Read more from the April 2010 Edition of the AACR Cancer Policy Monitor:
Top